Compare Oatly Group AB - ADR (OTLY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oatly Group AB - ADR vs TransMedics Group Inc — how do they compare? Oatly Group AB - ADR trades at $12.53 (market cap $402.73M), while TransMedics Group Inc trades at $86.4 (market cap $3.00B). The key difference: TransMedics Group Inc is far larger — about 7.4× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| OTLY | TMDX | |
|---|---|---|
Market Cap | $402.73M | $3.00B |
Sector | Consumer Staples | Technology |
52-Week High | $18.09 | $150.42 |
52-Week Low | $8.03 | $61.99 |
Enterprise Value | $907.14M | $3.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oatly (OTLY) trades at $13.52, down 3.98% today, with a bullish technical signal from a recent golden cross but bearish moving averages. Revenue growth improved to $862.46M in 2025, yet net losses persist at -$152.77M. The company raised its 2026 revenue outlook after Q2 results, driving positive sentiment from news outlets like Seeking Alpha on July 22, 2026.
Outlook hinges on margin expansion and path to profitability, with risks from high debt and cash burn. Analysts are mixed (44% buy, 50% hold), reflecting optimism on operational turnaround but caution on financial sustainability. Key catalysts include product innovation and market expansion, though negative cash flows and equity erosion pose significant investor risks.
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings results. The company reported strong revenue growth to $605.49M in 2025, with a net income margin of 22.69%, though profitability is expected to moderate in 2026. Recent news highlights ongoing legal investigations into fiduciary duties alongside positive coverage of growth initiatives in kidney transplantation and European expansion.
The stock presents a growth opportunity with analyst consensus pointing to a $99.57 price target, but risks include margin pressure from heavy investments and legal uncertainties. Earnings misses in recent quarters and a projected decline in net income for 2026 warrant caution, though institutional interest remains with a bullish rating from 69% of analysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
